Enanta Pharmaceuticals (ENTA) Retained Earnings: 2012-2025
Historic Retained Earnings for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to -$404.9 million.
- Enanta Pharmaceuticals' Retained Earnings fell 25.35% to -$404.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$404.9 million, marking a year-over-year decrease of 25.35%. This contributed to the annual value of -$404.9 million for FY2025, which is 25.35% down from last year.
- As of Q3 2025, Enanta Pharmaceuticals' Retained Earnings stood at -$404.9 million, which was down 4.84% from -$386.2 million recorded in Q2 2025.
- Enanta Pharmaceuticals' Retained Earnings' 5-year high stood at $97.2 million during Q1 2021, with a 5-year trough of -$404.9 million in Q3 2025.
- In the last 3 years, Enanta Pharmaceuticals' Retained Earnings had a median value of -$294.2 million in 2024 and averaged -$287.2 million.
- Data for Enanta Pharmaceuticals' Retained Earnings shows a maximum YoY plummeted of 824.08% (in 2023) over the last 5 years.
- Over the past 5 years, Enanta Pharmaceuticals' Retained Earnings (Quarterly) stood at $18.5 million in 2021, then tumbled by 653.41% to -$102.2 million in 2022, then plummeted by 135.31% to -$240.4 million in 2023, then tumbled by 43.65% to -$345.3 million in 2024, then decreased by 25.35% to -$404.9 million in 2025.
- Its last three reported values are -$404.9 million in Q3 2025, -$386.2 million for Q2 2025, and -$368.0 million during Q1 2025.